Heart HealthGLP-1 Peptides Cut Cardiovascular Risk by Targeting Dangerous Ceramides
A Physionic video explores a newly uncovered mechanism explaining how GLP-1 peptides such as semaglutide and liraglutide reduce cardiovascular risk — independent of weight loss alone. The key player appears to be ceramides, a class of bioactive lipids secreted by fat tissue that damage blood vessel walls, increase oxidative stress, and worsen vascular function. One ceramide in particular has emerged as especially hazardous to cardiovascular health. Clinical trials including the SELECT trial and the S-LiTE trial provide supporting evidence that GLP-1 therapies improve vascular endothelial function and reduce inflammatory markers. The video synthesizes five studies to argue that ceramide reduction may be a central mechanism behind the cardiovascular benefits of incretin-based therapies, with implications for how clinicians and health-conscious individuals think about obesity, metabolic health, and heart disease prevention.
